Claims for Patent: 12,213,967

Summary for Patent: 12,213,967

Title:	Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoropheyl)-3-phenylurea
Abstract:	Provided herein are low impurity compositions comprising a compound representedwhich are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Inventor(s):	Michael D. Kaufman, Scott Bone, Corey Bloom, Fred Jordan
Assignee:	Deciphera Pharmaceuticals LLC
Application Number:	US18/795,683
Patent Claims:	1. A solid dispersion comprising a compound represented by Formula (I): and hydroxypropylmethyl cellulose acetate succinate, wherein the compound is present with a purity of greater than 90% as determined by HPLC. 2. The solid dispersion of claim 1, wherein the compound is present with a purity of greater than 95% as determined by HPLC. 3. The solid dispersion of claim 1, wherein the compound is present with a purity of greater than 97% as determined by HPLC. 4. The solid dispersion of claim 1, wherein the compound is present with a purity of greater than 99% as determined by HPLC. 5. A pharmaceutical composition comprising: a solid dispersion comprising: a compound represented by Formula (I) or pharmaceutically acceptable salt thereof, and hydroxypropylmethyl cellulose acetate succinate; and wherein the pharmaceutical composition comprises one or more anilinic substances present in an amount equal to or less than about 10% by weight based on the weight of the compound of Formula (I) present in the composition. 6. The pharmaceutical composition of claim 5, wherein the one or more anilinic substances is present in an amount equal to or less than about 5% by weight based on the weight of the compound of Formula (I) present in the composition. 7. The pharmaceutical composition of claim 5, wherein the one or more anilinic substances is present in an amount equal to or less than about 3% by weight based on the weight of the compound of Formula (I) present in the composition. 8. The pharmaceutical composition of claim 5, wherein the one or more anilinic substances is present in an amount equal to or less than about 1% by weight based on the weight of the compound of Formula (I) present in the composition. 9. The pharmaceutical composition of claim 5, wherein the one or more anilinic substances is present in an amount equal to or less than about 0.5% by weight based on the weight of the compound of Formula (I) present in the composition. 10. A pharmaceutical composition, comprising: (i) a solid dispersion, wherein the solid dispersion comprises: (a) a compound represented by Formula (I): and (b) hydroxypropyl methyl cellulose acetate succinate. 11. A pharmaceutical composition, comprising: a solid dispersion comprising: (a) 50 mg of a compound represented by Formula (I): and (b) hydroxypropyl methyl cellulose acetate succinate.